Mersana Therapeutics, Inc.
NaPi2b-targeted antibody-drug conjugates and methods of use thereof
Last updated:
Abstract:
This disclosure provides NaPi2b-targeted antibody-drug conjugates (e.g., NaPi2b-targeted antibody-polymer-drug conjugates) that specifically bind to the extracellular region of SLC34A2, and to methods of using such conjugates in a variety of therapeutic, diagnostic, and prophylactic indications.
Status:
Grant
Type:
Utility
Filling date:
13 Mar 2017
Issue date:
16 Mar 2021